Your browser doesn't support javascript.
loading
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
Davids, Matthew S; Lampson, Benjamin L; Tyekucheva, Svitlana; Wang, Zixu; Lowney, Jessica C; Pazienza, Samantha; Montegaard, Josie; Patterson, Victoria; Weinstock, Matthew; Crombie, Jennifer L; Ng, Samuel Y; Kim, Austin I; Jacobson, Caron A; LaCasce, Ann S; Armand, Philippe; Arnason, Jon E; Fisher, David C; Brown, Jennifer R.
Afiliación
  • Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: matthew_davids@dfci.harvard.edu.
  • Lampson BL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Tyekucheva S; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biostatistics, Harvard T H Chan School of Public Health, Boston, MA, USA.
  • Wang Z; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biostatistics, Harvard T H Chan School of Public Health, Boston, MA, USA.
  • Lowney JC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Pazienza S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Montegaard J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Patterson V; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Weinstock M; Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Crombie JL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Ng SY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Kim AI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Jacobson CA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • LaCasce AS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Armand P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Arnason JE; Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Fisher DC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Brown JR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Lancet Oncol ; 22(10): 1391-1402, 2021 10.
Article en En | MEDLINE | ID: mdl-34534514
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirazinas / Sulfonamidas / Benzamidas / Leucemia Linfocítica Crónica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica / Compuestos Bicíclicos Heterocíclicos con Puentes / Anticuerpos Monoclonales Humanizados Tipo de estudio: Diagnostic_studies Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirazinas / Sulfonamidas / Benzamidas / Leucemia Linfocítica Crónica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica / Compuestos Bicíclicos Heterocíclicos con Puentes / Anticuerpos Monoclonales Humanizados Tipo de estudio: Diagnostic_studies Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article